Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2025 | $55.00 | Buy | Chardan Capital Markets |
| 2/11/2025 | $67.00 | Buy | Deutsche Bank |
| 10/10/2024 | $50.00 | Outperform | Raymond James |
| 10/1/2024 | $53.00 | Buy | H.C. Wainwright |
| 1/4/2024 | $62.00 | Buy | Citigroup |
| 12/8/2023 | $63.00 | Outperform | Robert W. Baird |
| 10/24/2023 | Overweight | Cantor Fitzgerald | |
| 4/25/2023 | $58.00 | Overweight | Cantor Fitzgerald |
Chardan Capital Markets initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $55.00
Deutsche Bank initiated coverage of Xenon Pharmaceuticals with a rating of Buy and set a new price target of $67.00
Raymond James resumed coverage of Xenon Pharmaceuticals with a rating of Outperform and set a new price target of $50.00
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. Conference Call/Webcast Information: Date:Monday, May 12, 2025 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:5532604 A live webcast of t
VANCOUVER, British Columbia and BOSTON, May 02, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced equity inducement grants to four new non-officer employees consisting of an aggregate of 78,600 share options and 1,800 performance share units ("PSUs"). All of the foregoing share options and PSUs were approved by the Compensation Committee of the Company's Board of Directors with an effective date of May 2, 2025 and were granted as inducements material to the employees entering into employment with the Company
Three epilepsy posters to be presented in scientific sessions at the American Academy of Neurology meetingLong-term 36-month data from the ongoing X-TOLE OLE study of azetukalner in focal onset seizures (FOS)Exploratory analysis of efficacy of azetukalner in FOS seizure sub-typesPatient survey findings on mental health and comorbidity burdens of FOS VANCOUVER, British Columbia and BOSTON, April 04, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced multiple presentations at the upcoming American A
DEFA14A - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
DEF 14A - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
8-K - Xenon Pharmaceuticals Inc. (0001582313) (Filer)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
SC 13G/A - Xenon Pharmaceuticals Inc. (0001582313) (Subject)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
4 - Xenon Pharmaceuticals Inc. (0001582313) (Issuer)
– OLE data shows sustained monthly reduction in seizure frequency, impressive seizure freedom rates, and consistent AE safety profile suggesting long-term efficacy and tolerability of azetukalner – Approximately one in three patients on drug for at least 36 months achieved seizure freedom for a period of one year or longer – Sustained monthly reductions in seizure frequency maintained at 85% at OLE study month 36 – Patient-reported survey data and literature review illustrate significant mental health and comorbidity burdens of focal onset seizures highlighting areas of unmet need for people living with epilepsy – New pre-clinical data shows Nav1.1 potentiator provides protection against
VANCOUVER, British Columbia and BOSTON, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced the appointment of Matthew D. Ronsheim, Ph.D. as Chief Operating Officer and a member of the Xenon senior executive team. In this new role, Dr. Ronsheim will lead Chemistry, Manufacturing and Controls (CMC), Program Management and Quality Assurance and as a member of the senior executive team will be responsible for providing strategic and operational leadership for the Company's pipeline of small molecule progr
BURNABY, British Columbia, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neurology-focused biopharmaceutical company, today announced the appointment of Andrea DiFabio as Chief Legal Officer and Corporate Secretary, effective immediately. Ms. DiFabio will provide strategic leadership and oversight of the planning and execution for Xenon's legal function on a global basis. Mr. Ian Mortimer, Xenon's President and Chief Executive Officer, stated, "We are very pleased to welcome Andrea to Xenon's senior leadership team in the newly created role of Chief Legal Officer. Andrea joins us at a time when we have multiple late-stage clinical programs underway with the
VANCOUVER, British Columbia and BOSTON, May 05, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its first quarter 2025 financial results and provide a business update after the close of U.S. financial markets on Monday, May 12, 2025. Conference Call/Webcast Information: Date:Monday, May 12, 2025 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:5532604 A live webcast of t
– Phase 3 topline data from azetukalner FOS epilepsy program planned for H2 2025 in support of NDA filing and potential commercial launch – First of three planned Phase 3 azetukalner MDD studies underway, with second study on track to initiate mid-year – Phase 3 azetukalner bipolar depression program planned for clinical trial initiation mid-year – Early-stage portfolio advancing with Kv7 and Nav1.7 IND filings anticipated in 2025 – Neurocrine collaboration achieves milestone with initiation of Phase 1 study of Nav1.2/Nav1.6 inhibitor – Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc.
VANCOUVER, British Columbia and BOSTON, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced it will report its fourth quarter 2024 financial results after the close of U.S. financial markets on Thursday, February 27, 2025. Conference Call/Webcast Information: Date:Thursday, February 27, 2025 Time:4:30 pm Eastern Time (1:30 pm Pacific Time) Webcast:Pre-register here Dial-In:(800) 715-9871 toll-free or (646) 307-1963 for international callers Conference ID:8120798 A live webcast of the company pre